Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).

ABSTRACT: Despite the marked success of molecular targeted therapy in lung cancer in this era of personalized medicine, its efficacy has been limited by the presence of resistance mechanisms. The prognosis of patients with lung cancer remains poor, and there is an unmet need to develop more effective therapies to improve clinical outcomes. The increasing insight into the human immune system has led to breakthroughs in immunotherapy and has prompted research interest in employing immunotherapy to treat lung cancer. Natural killer (NK) cells, which serve as the first line of defense against tumors, can induce the innate and adaptive immune responses. Therefore, the use of NK cells for the development of novel lung‑cancer immunotherapy strategies is promising. A growing number of novel approaches that

SUBMITTER: Zeng Y 

PROVIDER: S-EPMC8444189 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature